SCHEMBL801635

SCHEMBL801635

Cc1ccccc1-c1cc(Nc2n[nH]c3ccc(F)cc23)cc(-c2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 4/20 0.49
GSK3A P49840 3/20 0.42
GSK3B P49841 3/20 0.42
MAP2K4 P45985 1/20 0.38
MAPT P10636 1/20 0.38
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
EGFR P00533 1/20 0.37
RIPK2 O43353 3/20 0.37
GRM4 Q14833 3/20 0.37
ITK Q08881 1/20 0.36
GAK O14976 1/20 0.36
LCK P06239 1/20 0.36
TGFBR1 P36897 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801665 0.89 FADS1 (0.51) FADS1GSK3AGSK3BMAPTCYP1A2
SCHEMBL802027 0.88 FADS1 (0.46) FADS1GSK3AGSK3BMAPTAURKA
SCHEMBL801673 0.88 FADS1 (0.55) FADS1GSK3AGSK3BMAP2K4GRM4
SCHEMBL805524 0.86 FADS1 (0.47) FADS1GSK3AGSK3BMAP2K4MAPT
SCHEMBL801647 0.84 GSK3A (0.48) FADS1GSK3AGSK3BMAP2K4MAPT
SCHEMBL801639 0.82 GSK3A (0.50) FADS1GSK3AGSK3BMAPTCYP1A2
SCHEMBL802675 0.81 GSK3A (0.51) FADS1GSK3AGSK3BMAPTAURKA
SCHEMBL802250 0.80 FADS1 (0.45) FADS1GSK3AGSK3BMAPTCYP1A2
SCHEMBL802253 0.79 FADS1 (0.55) FADS1GSK3AGSK3BGRM4
SCHEMBL10267576 0.78 FADS1 (0.47) FADS1GSK3AGSK3BMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885GSK3A 2/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.